CYP2A6 genetic polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers

Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 4, 2015, Pages 263-268

  Hosono, Hiroki ^a   Kumondai, Masaki ^a   Arai, Tomio ^b   Sugimura, Haruhiko ^c   Sasaki, Takamitsu ^d   Hirasawa, Noriyasu ^a   Hiratsuka, Masahiro ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Tokyo Metropolitan Institute of Gerontology   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Activity score; CYP2A6; Genetic polymorphism; Smoker; Squamous cell lung cancer

Indexed keywords

CARCINOGEN; CYP2A6 PROTEIN, HUMAN; CYTOCHROME P450 2A6;

AGED; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CYP2A6 GENE; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; DEFICIENCY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; ODDS RATIO; RISK FACTOR; SQUAMOUS CELL CARCINOMA;

AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2A6; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING;

EID: 84938738362     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2015.04.002     Document Type: Article

References (36)

1. D.M. Parkin, F.I. Bray, and S.S. Devesa Cancer burden in the year 2000. The global picture Eur J Cancer 37 2001 S4 S66
2. J. Wang, J. Chen, X. Chen, B. Wang, K. Li, and J. Bi Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis PLoS One 6 2011 e28844
3. K. Fujita, and T. Kamataki Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase Environ Mol Mutagen 38 2001 339 346
4. M. Nakajima, T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashima, K. Inoue, and et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine Drug Metab Dispos 24 1996 1212 1217
5. C.L. Crespi, B.W. Penman, H.V. Gelboin, and F.J. Gonzalez A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6 Carcinogenesis 12 1991 1197 1201
6. M. Iscan, H. Rostami, M. Iscan, T. Guray, O. Pelkonen, and A. Rautio Interindividual variability of coumarin 7-hydroxylation in a Turkish population Eur J Clin Pharmacol 47 1994 315 318
7. M. Oscarson, R.A. McLellan, H. Gullsten, Q.Y. Yue, M.A. Lang, M.L. Bernal, and et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population FEBS Lett 448 1999 105 110
8. M. Oscarson, R.A. McLellan, H. Gullsten, J.A. Agundez, J. Benitez, A. Rautio, and et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism FEBS Lett 460 1999 321 327
9. N. Ariyoshi, Y. Sawamura, and T. Kamataki A novel single nucleotide polymorphism altering stability and activity of CYP2A6 Biochem Biophys Res Commun 281 2001 810 814
10. M. Miyamoto, Y. Umetsu, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh, and et al. CYP2A6 gene deletion reduces susceptibility to lung cancer Biochem Biophys Res Commun 261 1999 658 660
11. N. Ariyoshi, M. Miyamoto, Y. Umetsu, H. Kunitoh, H. Dosaka-Akita, Y. Sawamura, and et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers Cancer Epidemiol Biomarkers Prev 11 2002 890 894
12. M. Fujieda, H. Yamazaki, T. Saito, K. Kiyotani, M.A. Gyamfi, M. Sakurai, and et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers Carcinogenesis 25 2004 2451 2458
13. Y. Tamaki, T. Arai, H. Sugimura, T. Sasaki, M. Honda, Y. Muroi, and et al. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung Cancer in Japan Drug Metab Pharmacokinet 26 2011 516 522
14. N. Kumasaka, M. Aoki, Y. Okada, A. Takahashi, K. Ozaki, T. Mushiroda, and et al. Haplotypes with copy number and single nucleotide polymorphisms in CYP2A6 locus are associated with smoking quantity in a Japanese population PLoS One 7 2012 e44507
15. M.A. Loriot, S. Rebuissou, M. Oscarson, S. Cenee, M. Miyamoto, N. Ariyoshi, and et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population Pharmacogenetics 11 2001 39 44
16. W. Tan, G.F. Chen, D.Y. Xing, C.Y. Song, F.F. Kadlubar, and D.X. Lin Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population Int J Cancer 95 2001 96 101
17. C.A. Wassenaar, Q. Dong, Q. Wei, C.I. Amos, M.R. Spitz, and R.F. Tyndale Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk J Natl Cancer Inst 103 2011 1342 1346
18. T. Sobue, S. Yamamoto, M. Hara, S. Sasazuki, S. Sasaki, and S. Tsugane Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study Int J Cancer 99 2002 245 251
19. S.D. Goodz, and R.F. Tyndale Genotyping human CYP2A6 variants Methods Enzymol 357 2002 59 69
20. K. Kiyotani, M. Fujieda, H. Yamazaki, T. Shimada, F.P. Guengerich, A. Parkinson, and et al. Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and caucasians Drug Metab Dispos 17 2002 482 487
21. M. Haberl, B. Anwald, K. Klein, R. Weila, C. Fuß, A. Gepdiremen, and et al. Three haplotypes associated with CYP2A6 phenotypes in caucasians Pharmacogenet Genomics 15 2005 609 624
22. C. Xu, Y.S. Rao, B. Xu, E. Hoffmann, J. Jones, E.M. Sellers, and et al. An in vivo pilot study characterizing the new CYP2A6∗7,∗8, and∗10 alleles Biochem Biophys Res Commun 290 2002 318 324
23. K.I. Nunoya, T. Yokoi, K. Kimura, T. Kainuma, K. Satoh, M. Kinoshita, and et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans J Pharmacol Exp Ther 289 1999 437 442
24. M. Piliguian, A.Z. Zhu, Q. Zhou, N.L. Benowitz, J.S. Ahluwalia, L. Sanderson Cox, and et al. Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo Pharmacogenet Genomics 24 2014 118 128
25. M. Nakajima, T. Fukami, H. Yamanaka, E. Higashi, H. Sakai, R. Yoshida, and et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations Clin Pharmacol Ther 80 2006 282 297
26. K. Kiyotani, H. Yamazaki, M. Fujieda, S. Iwano, K. Matsumura, S. Satarug, and et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6∗9) Pharmacogenetics 13 2003 689 695
27. A. Gaedigk, S.D. Simon, R.E. Pearce, L.D. Bradford, M.J. Kennedy, and J.S. Leeder The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype Clin Pharmacol Ther 83 2008 234 242
28. M.S. Islam, M.U. Ahmed, M.S. Sayeed, A.A. Maruf, A.G. Mostofa, S.M. Hussain, and et al. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population Clin Chim Acta 416 2013 11 19
29. C.A. Wassenaar, Y. Ye, Q. Cai, M.C. Aldrich, J. Knight, M.R. Spitz, and et al. CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers-findings from two independent populations Carcinogenesis 36 2015 99 103
30. C. Kiyohara, K. Takayama, and Y. Nakanishi CYP2A13, CYP2A6, and the risk of lung adenocarcinoma in a Japanese population J Health Sci 51 2005 658 666
31. Y. Gu, S. Zhang, B. Lai, X. Zhan, and Y. Zhang Frequency of CYP2A6 gene deletion and its relation to risk of lung cancer Zhongguo Fei Ai Za Zhi 8 2005 297 299
32. T. Liu, C.B. Xie, W.J. Ma, and W.Q. Chen Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies Environ Mol Mutagen 54 2013 133 140
33. Z.B. Liu, J. Shu, L.P. Wang, C. Jin, and Z.X. Lou Cytochrome P450 2A6 deletion polymorphism and risk of lung cancer: a meta-analysis Mol Biol Rep 40 2013 5255 5259
34. L. Wang, W. Zang, J. Liu, D. Xie, W. Ji, Y. Pan, and et al. Association of CYP2A6∗4 with susceptibility of lung cancer: a meta-analysis PLoS One 8 2013 e59556
35. K.A. Schoedel, E.B. Hoffmann, Y. Rao, E.M. Sellers, and R.F. Tyndale Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians Pharmacogenetics 14 2004 615 626
36. H. Takeuchi, K. Saoo, M. Yokohira, M. Ikeda, H. Maeta, M. Miyazaki, and et al. Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice Cancer Res 63 2003 7581 7583